On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the May 2026 CRG meeting. Actions in this consultation include:
- Rivastigmine twice-weekly patches – add statement to formulary that products are not interchangeable and recommend prescribing by brand
- Trixeo Aerosphere for COPD – GREEN
- NICE TA1148 – sodium zirconium cyclosilicate – AMBER; existing shared care protocol to be reviewed
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Wednesday 15th July 2026. To take part, visit the consultations page.
Guidelines and pathways
The following guidelines and pathways are also open for consultation:
- CKD toolkit for primary care – this consultation will run for six weeks and closes at 5pm on Wednesday 15th July
- Valproate guide – this consultation will run for two weeks and closes at 5pm on Wednesday 17th June